BeiGene, Ltd. (ONC) shares ended the last trading session 3.2% higher at $244.20. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

BeiGene (ONC) has received FDA approval for Tevimbra for first-line esophageal cancer with chemo. Read more here.

For the quarter ended December 2024, BeiGene, Ltd. (ONC) reported revenue of $1.13 billion, up 77.8% over the same period last year. EPS came in at -$1.43, compared to -$3.53 in the year-ago quarter.

Beigene, Ltd. (NASDAQ:ONC – Get Free Report)’s stock price gapped down prior to trading on Monday following insider selling activity. The stock had previously closed at $271.80, but opened at $255.83.

BeiGene (NasdaqGS:ONC) experienced a significant 29% price increase over the last quarter, supported by the FDA approval of TEVIMBRA for treating esophageal squamous cell carcinoma, a key development ...

Bank of America upgraded shares of Beigene (NASDAQ:ONC – Free Report) from a neutral rating to a buy rating in a report published on Monday morning, MarketBeat.com reports. The brokerage currently has ...

Below is Validea's guru fundamental report for BEIGENE LTD (ADR) (ONC). Of the 22 guru strategies we follow, ONC rates highest using our P/B Growth Investor model based on the published strategy ...

First on this list of the top NASDAQ stem cell company stocks is multinational ... Biotechnology company BeiGene specializes in the development of drugs for cancer treatment across a broad range ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and BeiGene, Ltd. (ONC). But which of these two stocks ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...